China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced a tripartite strategic cooperation agreement with the Zimbabwe National Biotechnology Authority (Zimbabwe NBA) and the International Centre for Genetic Engineering and Biotechnology China Regional Research Centre (ICGEB). This collaboration aims to enhance vaccine production capabilities in Zimbabwe, starting with the COVID-19 vaccine and expanding to a broader range of vaccine varieties.
Technical Support and Localized Production Initiatives
Under the terms of the agreement, Recbio will work closely with the ICGEB China Regional Research Centre to provide comprehensive technical support for vaccine production in Zimbabwe. This support includes personnel training, plant design, clinical trials, sub-packaging technology, and stock solution technology transfer. The initiative is expected to significantly contribute to localized vaccine production efforts in Zimbabwe and across Africa, addressing critical public health needs.
Strengthening Biotechnology in Zimbabwe
The Zimbabwe National Biotechnology Authority, established in 2006, promotes the application of both traditional and cutting-edge biotechnology in various fields, including medicine and agriculture. The ICGEB, founded in 1983 with backing from the United Nations Industrial Development Organization (UNIDO), has created interactive networks with over 65 member states, achieving notable success in scientific research, training, and technology transfer to industry. This partnership with Recbio is set to further bolster Zimbabwe’s biotechnology landscape.-Fineline Info & Tech
